Sanara MedTech Shareholder Rights Firm Investigates $33M Sale to MiMedx
Event summary
- Halper Sadeh LLC is investigating the $33M sale of Sanara MedTech (SMTI) to MiMedx over potential undervaluation and process concerns.
- Deal terms: $33.00 in cash + 0.4735 shares of MiMedx stock per Sanara share.
- Firm alleges board may have failed to secure best price or disclose material information.
- Investigation focuses on potential breaches of fiduciary duties and securities laws.
The big picture
This investigation highlights growing shareholder activism in mid-market healthcare acquisitions, particularly around valuation fairness. The case could set a precedent for how boards conduct sales processes and disclose information in similar transactions. With medical device consolidation accelerating, scrutiny of deal terms will likely intensify.
What we're watching
- Valuation Scrutiny
- Whether Sanara's $33M sale price reflects fair market value given the firm's investigation.
- Regulatory Risk
- The potential for legal challenges to delay or derail the acquisition process.
- Board Accountability
- How this case may influence future M&A governance standards in medical technology.
Related topics